The share price of immutep is weak again. There are no good times at stock markets for small biotech without revenues. A potential mid term capital increase for financing the p3 in NSLC will be in this market conditions very painful for excisting shareholders because off huge dilution. So what maybe the solution for us? An outlicensing deal with big pharma. Immutep will have to demonstrate the market participants that they can monetarise the excellent study results without further capital increase for starting P3. The colloboration update is in my opinion a step in this direction.
Further Development
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 42705 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |